GLP-1 RAs are not indicated for type 1 diabetes and should not be used during pregnancy or breastfeeding unless the benefits clearly outweigh potential risks
Porous silicon microparticles enable sustained release of GLP-1R agonist peptides for the treatment of Type 2 diabetes
All the GLPs can cause gastrointestinal side effects, from tummy upset, constipation, nausea to diarrhea
Clearly communicate aspiration risk to the team to align preparation and roles There are no formal ED-specific guidelines, but EM and anesthesia literature consistently emphasize increased vigilance rather than major practice change
Medically reviewed by: Jayden Lee, PharmD, EMBA Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes